Objective To summarize and review the clinical translational research progress on cancer-associated fibroblasts (CAFs) in triple-negative breast cancer (TNBC), aiming to provide new ideas for the treatment of TNBC. Method Relevant literature on studies of CAFs in TNBC in recent years was retrieved and reviewed. Results As the most important stromal cell component in the tumor microenvironment (TME), CAFs participate in tumor growth, invasion, immune suppression, and therapy resistance by secreting cytokines and chemokines and remodeling the extracellular matrix. Based on this, the clinical translational strategies targeting CAFs in TNBC mainly include targeting CAFs-specific markers and their oncogenic pathways, inhibiting or reversing CAFs activation and recruitment, and developing novel therapies such as photothermal therapy. Conclusions In the face of clinical challenges such as therapy-resistant TNBC, research on CAFs provides new insights for addressing the complexity of the TME. Although targeting CAFs is challenging due to their heterogeneity, current clinical research and trials have confirmed that combining CAFs-targeting strategies with immunotherapy or chemotherapy is feasible. This approach is expected to become a new treatment modality for TNBC.
Citation：
HU Sichang, LI Na, CHEN Lijuan, DANG Zheng. Cancer-associated fibroblasts in triple-negative breast cancer: progress in clinical translational research. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2026, 33(2): 271-277. doi: 10.7507/1007-9424.202508102
Copy
Copyright ? the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. |
|
| 2. |
|
| 3. |
|
| 4. |
|
| 5. |
|
| 6. |
|
| 7. |
|
| 8. |
|
| 9. |
|
| 10. |
|
| 11. |
|
| 12. |
|
| 13. |
|
| 14. |
|
| 15. |
|
| 16. |
|
| 17. |
|
| 18. |
|
| 19. |
|
| 20. |
Fang J , Jiang Q , Yang X , et al. Construction of targeting GPR77+CD10+ lipid nanoparticles and validation of targeting capability in vitro and in vivo. Current Res Biotechnol, 2025, 9: 100291. doi: 10.1016/j.crbiot.2025.100291.
|
| 21. |
|
| 22. |
|
| 23. |
|
| 24. |
|
| 25. |
|
| 26. |
|
| 27. |
|
| 28. |
|
| 29. |
|
| 30. |
Zhang P, Qin C, Liu N, et al. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials, 2022, 284: 121518. doi: 10.1016/j.biomaterials.2022.121518.
|
| 31. |
|
| 32. |
|
| 33. |
|
| 34. |
|
| 35. |
|
| 36. |
|
| 37. |
|
| 38. |
|
| 39. |
|
| 40. |
|
| 41. |
|
| 42. |
|
| 43. |
|
| 44. |
|
| 45. |
|
| 46. |
|
| 47. |
|
| 48. |
Rodriguez AB, Facklam A, Trickett J, et al. Mouse analog of micvotabart pelidotin sensitizes a refractory syngeneic breast cancer model to anti-PD1 therapy [abstract] // Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2025 Oct 22-26. Boston, MA. Philadelphia (PA): AACR. Mol Cancer Ther, 2025, 24(10 Suppl): Abstract nr A115. doi: org/10.1158/1535-7163.TARG-25-A115.
|
| 49. |
|
| 50. |
|
| 51. |
|
| 52. |
|
| 53. |
|
| 54. |
|
| 55. |
|
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20. Fang J , Jiang Q , Yang X , et al. Construction of targeting GPR77+CD10+ lipid nanoparticles and validation of targeting capability in vitro and in vivo. Current Res Biotechnol, 2025, 9: 100291. doi: 10.1016/j.crbiot.2025.100291.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30. Zhang P, Qin C, Liu N, et al. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials, 2022, 284: 121518. doi: 10.1016/j.biomaterials.2022.121518.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 39.
- 40.
- 41.
- 42.
- 43.
- 44.
- 45.
- 46.
- 47.
- 48. Rodriguez AB, Facklam A, Trickett J, et al. Mouse analog of micvotabart pelidotin sensitizes a refractory syngeneic breast cancer model to anti-PD1 therapy [abstract] // Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2025 Oct 22-26. Boston, MA. Philadelphia (PA): AACR. Mol Cancer Ther, 2025, 24(10 Suppl): Abstract nr A115. doi: org/10.1158/1535-7163.TARG-25-A115.
- 49.
- 50.
- 51.
- 52.
- 53.
- 54.
- 55.
1/5
WeChat